Analyst Activity – Cann Reiterates Hold on Clovis Oncology (NASDAQ:CLVS)

ME Staff
-
0

Analyst Ratings For Clovis Oncology (NASDAQ:CLVS)

Today, Cann reiterated its Hold rating on Clovis Oncology (NASDAQ:CLVS).

There are 6 hold ratings, 10 buy ratings on the stock.

The current consensus rating on Clovis Oncology (NASDAQ:CLVS) is Buy (Score: 2.63) with a consensus target price of $79.50 per share, a potential 7.34% downside.

Some recent analyst ratings include

  • 7/31/2017-Cann Reiterated Rating of Hold.
  • 7/7/2017-Gabelli initiated coverage with a Buy rating.
  • 6/23/2017-Oppenheimer Holdings, Inc. initiated coverage with a Market Perform rating.
  • 6/22/2017-SunTrust Banks, Inc. Reiterated Rating of Buy.
  • 6/20/2017-J P Morgan Chase & Co Reiterated Rating of Overweight.
  • 6/20/2017-Goldman Sachs Group, Inc. (The) Reiterated Rating of Neutral.

Recent Insider Trading Activity For Clovis Oncology (NASDAQ:CLVS)
Clovis Oncology (NASDAQ:CLVS) has insider ownership of 17.40% and institutional ownership of 90.01%.

  • On 7/17/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $91.56 per share and the total transaction amounting to $274,680.00. View SEC Filing
  • On 6/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $61.82 per share and the total transaction amounting to $185,460.00. View SEC Filing
  • On 5/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $47.39 per share and the total transaction amounting to $142,170.00. View SEC Filing
  • On 4/17/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $56.02 per share and the total transaction amounting to $168,060.00. View SEC Filing
  • On 3/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $66.99 per share and the total transaction amounting to $200,970.00. View SEC Filing
  • On 11/2/2015 Erle T. Mast, CFO, sold 3,000 with an average share price of $105.56 per share and the total transaction amounting to $316,680.00. View SEC Filing
  • On 10/28/2015 Lindsey Rolfe, insider, sold 4,000 with an average share price of $98.02 per share and the total transaction amounting to $392,080.00. View SEC Filing

Recent Trading Activity for Clovis Oncology (NASDAQ:CLVS)
Shares of Clovis Oncology closed the previous trading session at 85.46 down -12.56 -12.82% with 2,366,057 shares trading hands.